Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Accept all cookies' we'll assume that you are happy to receive all cookies and you won't see this message again. If you click 'Reject all non-essential cookies' only necessary cookies providing core functionality such as security, network management, and accessibility will be enabled. Click 'Find out more' for information on how to change your cookie settings.

Contact information

Email
samuel.provstgaard-morys@ndm.ox.ac.uk

Research groups

Malaria Programme: Pre-erythrocytic Vaccines

Samuel Provstgaard-Morys

DPhil Student

Recent publications

A phase 1b clinical trial to determine the safety, tolerability and immunogenicity of simian adenovirus and poxvirus vectored vaccines against a Mycobacterium avium complex subspecies in patients with active Crohn's disease

Sanderson J. et al, (2025), eBioMedicine, 113, 105570 - 105570

A randomised trial of malaria vaccine R21/Matrix-M™ with and without antimalarial drugs in Thai adults

Hanboonkunupakarn B. et al, (2024), npj Vaccines, 9

Safety and immunogenicity of varied doses of R21/Matrix-M™ vaccine at three years follow-up: A phase 1b age de-escalation, dose-escalation trial in adults, children, and infants in Kilifi-Kenya

Sang S. et al, (2024)

The public health impact and cost-effectiveness of the R21/Matrix-M malaria vaccine: a mathematical modelling study

Schmit N. et al, (2024), The Lancet Infectious Diseases, 24, 465 - 475

Safety and efficacy of malaria vaccine candidate R21/Matrix-M in African children: a multicentre, double-blind, randomised, phase 3 trial

Datoo MS. et al, (2024), The Lancet, 403, 533 - 544